SCHEMBL4533427

SCHEMBL4533427

COc1ccc(-c2c(-c3ccccc3)oc3ncnc(OCC(COCC(=O)O)OC)c23)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.55
ALDH1A1 P00352 3/20 0.55
HPGD P15428 2/20 0.55
UBE2N P61088 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
TEK Q02763 7/20 0.51
KDR P35968 5/20 0.51
AURKA O14965 1/20 0.48
CHEK1 O14757 2/20 0.47
CDK1 P06493 1/20 0.47
TNK2 Q07912 1/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
EGFR P00533 1/20 0.45
GSK3B P49841 1/20 0.44
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
MERTK Q12866 1/20 0.43
HIF1A Q16665 2/20 0.43
PPARG P37231 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4527320 0.90 KDM4E (0.56) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL6751211 0.90 KDM4E (0.50) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL4530912 0.88 KDM4E (0.60) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL6748469 0.88 KDM4E (0.64) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL4521405 0.86 KDM4E (0.58) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL4539975 0.84 KDM4E (0.55) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL4531398 0.83 KDM4E (0.63) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL6749029 0.83 KDM4E (0.63) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL6751199 0.82 KDM4E (0.53) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL4527177 0.82 KDM4E (0.53) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318475-A1 Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof BAYER HEALTHCARE AG (DE) 2009-12-24 US disclosed
WO-2008131858-A2 USE OF ACYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-11-06 WO disclosed
WO-2007079862-A1 NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES BAYER HEALTHCARE AG (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318475-A1 Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof DPYD, PNPO, TPMT KDM4E 3800/4885ALDH1A1 318/4885HPGD 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.